Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on the call as well. Today's agenda is as follows. I am starting by recapping the Q3 from a financial summary point of view. Then, let's also spend a bit of time on where we have been focusing during Q3 and how things like integration and other topics have been progressing throughout the quarter. Jukka is going to continue by going through the financials. Then also, of course, the guidance. Then we move for the Q&A.
Q3. In all aspects, this is a historic quarter for Revenio. So during Q3, we have doubled our scale. We have kicked off the integration, of course. And if we look from the pure numbers perspective, net sales were 58.8 million during the Q3. If you look at the reported numbers perspective compared to old Revenio, the growth is roughly a bit less than 130%. And we have also been increasing the transparency. Regarding reporting, we are providing more detail on our region-based numbers. We had an extremely strong growth in our largest region, which is EMEA and LatAm, ending up at 34.3 million. If you look at the other regions like APAC, those remained soft during Q3. And then we have been focusing on the USA. Our organization changed, especially on the sales and marketing side. I will come back to that later. So we had a slight decline year on year if we compare to the pro forma in the USA. But I will return to that later. And the reason for that is that we reorganized the entire sales and marketing organization in order to be able to provide long-term sustainable growth. Also in the USA, adjusted EBITDA was 8.7 million. So compared to last year. So that's a 30% increase. And also, we have become stronger in terms of our cash flow. 5.5 million up from 3 million. And then we are advancing the integration as planned, on an even faster schedule than what we originally planned. So far, we have been able to secure, on a run-rate basis, 25% of the targeted 20 million EBITDA uplift. Regarding the Q3, the focus of the organization has been really building the base for long-term sustainable growth. If we look back at the old Revenio where we were selling tonometers, fundus imaging devices, perimeters, probes, and software solutions like Icare ILLUM. Now the company is totally different, and the priorities are totally different. During Q3, we have, of course, clarified the new combined company strategy. We communicated that during the CMD. And if you recall. So the strategy is geared around delivering the shift from vision care to the connected eHealth. We have implemented a completely new organizational and operative model. And here I want to emphasize the big revamp of the organization in the USA. That includes all the functions. And of course, especially the US sales and marketing department. We organized the whole team now in a totally different way into three regions. Then new team members are also in place. It is self-evident that this is having a slight impact on the sales performance in the USA. But the reason we did this is, of course, that it enables us to grow in the long run. The third topic is what I mentioned already regarding the organization and related changes there, which are, of course, having an impact on the opex side, especially in the USA. We have been able to advance the integration extremely well on that front. And as of today, looking at Q4. We still have actions ongoing regarding the OpEx activities, but bit by bit, the focus is starting to move more towards harnessing the commercial synergies. Then our net debt to EBITDA ratio was quite high, a bit over five. We have been working, of course, during Q3 to secure the rights issue, which was oversubscribed. So that went well. And after the review period, the leverage is now reduced to a bit more than three. But Jukka is coming back to this one. And if we now start to look at Q4, we can see where the focus currently is. We still have activities and actions in our plans regarding the OpEx synergies, but we are shifting our focus a bit more now. Also the focus to harness the forthcoming commercial synergies. And what I mean with this is that we already have clear active cross-selling plans in place, and we are starting to execute them. We have plans on how to optimize the sales channels globally, so the US part is done. And then, of course, we are putting more emphasis on key account coverage as we now have a much wider product portfolio. With all these actions, we really have a feeling that we are having good momentum for 2027 as well.
We have discussed many times in these calls whether there are new products coming, how we are allocating capital, and this is the latest case on that front. So during the Q3, we launched a new iCare tonometer called. iCare IC1000. Extremely well received among the distributor partners. And then, of course, our clinical clients. So we introduced the GuideCam alignment. So you have an excellent alignment feature, including the full-on automation and the camera on the screen. Then, of course, the SmartCradle allows wireless connectivity to clinical workflows, utilizing the same technology as the previous model. It is anesthesia-free, uses the rebound technology, and will in the long run also enable increased consumable sales. And then if you also look to the future. So, the strategy is not going to change. So in the product categories, what we have now as a combined company. We are going to continue to invest in the future in R&D in order to bring new innovations to the market. But this is the latest product which we launched during the Q3. But let's jump to the financials. So, over to you. Thank you, Jouni. Let's move to the key figures. And as a reminder, this is the first quarter where we have the full Visionix integration in our numbers, starting from the beginning of the quarter, as we only had one month of their results in the second quarter. But when looking at net sales, net sales growth with the reported numbers, like Jouni highlighted, was almost 130%. So net sales have more than doubled when you look at the quarterly numbers. Also, when looking at year-to-date numbers of 125 million, net sales are also growing by almost 60%. So the scale is totally different. Also, when looking at the companies and comparables, we are quite a different company nowadays than one year back as you can see, when looking at the profitability metrics, reaching an adjusted EBITA of €8.7 million compared to €6.6 million in quarter three, 2025, which is 14.7% of net sales compared to 25.7% in the comparable period. It is good to note that in absolute terms, this adjusted EBITA is more than 30% up when looking at the real euros. The new scale is also seen in our earnings line. And then when looking at the leverage metrics and balance sheet metrics, the equity ratio is 32% and gearing is 149%. And this is, of course, before the rights issue took place in October, because we report the quarterly numbers, but still sequentially. Also, the leverage metrics were improving and the balance sheet strengthened between the quarters. So that is really relevant as well.
Then let's go into more detail regarding the net sales and net sales growth. So, quarter three net sales were €58.8 million. When we look at it organically, this means we compare it to the pro forma figures for the combined company from the third quarter of 2025. Our growth was basically flat, even looking at the third quarter year-to-date. But when looking under the numbers in different regions, we had a really strong performance in EMEA and Latam. And when we look at it organically, it had really strong growth driven by the big countries, Italy, France and our global customers as well, and supported by this multimodal offering. We have a strong overall offering. And then, like Jouni highlighted, the challenging market environment has continued in the DACH region and in North America. The reorganization we did impacted the sales numbers during the quarter. Three, 2026.
And then let's look more in detail. Our profitability and adjusted EBITA, starting maybe first from the gross margin. So gross margin declined to 63.2% compared to 71.5% one year back. And it has a nine percentage point dilution impact coming from the Visionix lower margin profile. So now we have Visionix in our whole quarter numbers. And that is visible also in the gross margin numbers, as you see. And then a few other items impacting our profitability and gross margins. Still, the unit cost increases regarding the electronic components had a negative impact on our gross margin overall and also our sales mix. So those two together had around a 2 percentage point negative impact on the gross margin. But then at the same time, we had a positive impact coming from the North America business and tariff refunds overall. There was around a three percentage point positive impact on our gross margin for the quarter. As I highlighted previously, adjusted EBITA was €8.7 million for the quarter compared to €6.6 million in the comparable period. So roughly more than 30% up in earnings when looking at the adjusted EBITA line. And then let's move to the cash flow. Cash flow from operations turned positive for the third quarter at €5.5 million. And improved from the last year. Reported numbers in quarter three were €3 million. And that was driven by the strong working capital development during the quarter. And even though it included around 2 million in one-off payments regarding our integration, which is, of course, ongoing. And when looking more in detail at the balance sheet, of course, the balance sheet metrics are reflected by the Visionix acquisition. When looking at the third quarter situation, we had a term loan of 130 million. A vendor loan of 17 million euros. At that moment, we still had the bridge-to-equity facility of €80 million. So around 232 million net debt at the end of the quarter. Three. But still, our net gearing improved from 159% at the end of Q2 to 149%, and also the equity ratio went up from 31% at the end of Q2 to 32%. We had cash balances of €17 million at the end of the quarter. And also, this net debt to adjusted EBITDA ratio went down from 5.3. End of quarter 2 to 5.1. So all the balance sheet metrics improved even though this rights issue was not completed. When we look at the situation at the end of September. And when we look at the situation now, during October we were able to close the rights issue, which was fully oversubscribed. And by the way, thanks to everyone who joined the rights issue. And we have already, as of today, paid out the bridge to equity facility of €80 million. But of course, when we report these Q3 numbers, those are not yet visible here. And overall, we continue our profitable growth. We also improve our cash flow, which will improve the leverage metrics for the coming quarters and going forward. Then, regarding our shareholders' register at the end of September, maybe I will highlight a few points here regarding the Visionix acquisition. There are a few new names in the table coming from France, with Caravelle Capital SAS as a new owner owning more than 5% of the company. Also, Marc Abitbol became an owner, owning 1.5% of the company. Regarding the Visionix acquisition and, of course, overall, we have almost 50% of our owners outside Finland, which is quite a good number for a listed company. Money overall. And then let's go to our financial guidance. We have specified our financial guidance regarding net sales, and we have narrowed down the top end of the guidance. Our previous financial guidance for the net sales was between 190 million and 205 million. Our specified guidance is between 190 million up to 200 million. Regarding profitability, our guidance remains unchanged. And the changes are coming from the regional impacts. As we commented, we saw strong performance in Latam, but the reorganization in North America impacted our sales in the third quarter. And the challenging market environment continues in the APAC region. So all these are reflected in our new guidance.
Thank you.